<DOC>
	<DOCNO>NCT01850355</DOCNO>
	<brief_summary>The main objective exploratory 8-week pilot study evaluate safety efficacy buspirone treatment anxiety youth ( age 6-17 year ) autism spectrum disorder . The study result use generate hypothesis large randomize control clinical trial explicit hypothesis sufficient statistical power .</brief_summary>
	<brief_title>An Open-Label Trial Buspirone Treatment Anxiety Youth With Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Male female participant 6 17 year age Fulfills diagnosis autism spectrum disorder meet DSMIVTR PDD diagnostic criterion autistic disorder , Asperger 's disorder , PDDNOS establish clinical diagnostic interview Participants score ≥13 Pediatric Anxiety Rating Scale ( PARS ) Participants score ≥60 Anxiety/Depression subscale CBCL CGIAnxiety severity ≥ 4 Subjects psychotropic drug medication least 4 week prior initiate trial treatment stable , provided medication list Concomitant Medications section protocol . Subjects disruptive behavior disorder , mood , psychosis allow participate study provide meet exclusionary criterion I.Q . &lt; 70 DSMIVTR PDD diagnose Rett 's disorder , childhood disintegrative disorder History active seizure disorder ( EEG suggestive seizure activity and/or history seizure last 1 month ) Subjects medical condition treatment either jeopardize subject safety affect scientific merit study , include : Pregnant nursing female Organic brain disorder Uncorrected hypothyroidism hyperthyroidism Clinically significant abnormality ECG ( e.g. , QT prolongation , arrhythmia ) History renal hepatic impairment Clinically unstable psychiatric condition judge serious suicidal risk Current diagnosis schizophrenia History substance use ( except nicotine caffeine ) within past 3 month urine drug screen positive substance abuse Current treatment medication primary central nervous system activity ( specify Concomitant Medication section protocol ) A nonresponder history intolerance buspirone , treatment adequate dose duration determine clinician Subjects currently take monoamine oxidase inhibitor ( MAOI ) and/or CYP3A4 inducer inhibitor include nefazodone , diltiazem , verapamil , erythromaycin , itraconazole , rifampin .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Buspar</keyword>
	<keyword>Buspirone</keyword>
	<keyword>Pervasive Developmental Disorders</keyword>
</DOC>